Humanin

Humanin is a small peptide naturally produced in the mitochondria, the energy powerhouses of cells. It acts as a guardian against cellular stress. Research has focused on its ability to reduce cell death (apoptosis), oxidative damage, inflammation, and mitochondrial dysfunction in many tissues The emerging role of the mitochondrial-derived peptide humanin in stress resistance+2.

Because it helps cells survive under harsh conditions, scientists have explored Humanin's potential in conditions like neurodegenerative diseases, heart failure, diabetes, lung injury, and eye disorders Humanin and Its Pathophysiological Roles in Aging: A Systematic Review+1. Most evidence comes from animal studies and cell experiments. Human observational data also link higher natural Humanin levels to better metabolic health and lower oxidative stress Humanin: a mitochondrial signaling peptide as a biomarker for impaired fasting glucose-related oxidative stress+1.

So far, no human trials have tested Humanin supplementation as a treatment, so its therapeutic use remains investigational Humanin: a mitochondrial signaling peptide as a biomarker for impaired fasting glucose-related oxidative stress+1.

Humanin works through at least two main pathways. First, it binds to a receptor complex on the cell surface (involving CNTFR, WSX-1, and gp130), which triggers a cascade of signals inside the cell that promote survival Humanin and the Receptors for Humanin. This includes activating proteins like STAT3 and AKT, which tell the cell to stay alive and resist stress Involvement of tyrosine kinases and STAT3 in Humanin-mediated neuroprotection.

Second, Humanin can directly enter the cell and block BAX, a protein that would otherwise trigger cell death. By binding to BAX, Humanin prevents mitochondrial damage and keeps the cell functioning The emerging role of the mitochondrial-derived peptide humanin in stress resistance+1.

These actions together reduce inflammation, boost antioxidant defenses, and improve energy production. In animal models of stroke, traumatic brain injury, and diabetes, Humanin has been shown to limit injury and support recovery Enduring Effects of Humanin on Mitochondrial Systems in TBI Pathology+2.

Neuroprotection

Humanin was first discovered for its ability to protect neurons from Alzheimer's-related toxicity. In mice, potent analogs reduced brain damage after strokes, improved memory in Alzheimer's models, and preserved mitochondrial health in traumatic brain injury Humanin Is a Novel Neuroprotective Agent Against Stroke+2. Intranasal delivery has shown promise for reaching the brain in Parkinson's disease models Intranasal delivery of mitochondrial protein humanin rescues cell death and promotes mitochondrial function in Parkinson's disease.

Cardiovascular and Metabolic Health

Observational studies in humans found that higher blood levels of Humanin are linked to lower heart failure risk markers and less oxidative stress Abstract 4114198: Humanin Level is Inversely Correlated with NT-proBNP Level and Mortality in Heart Failure with Reduced Ejection Fraction+1. In diabetic animals, Humanin helped restore normal levels of metabolic hormones like leptin and ghrelin Humanin Restores Metabolic Hormone Homeostasis of Leptin, Ghrelin, Irisin and Asprosin in Streptozotocin-Induced Diabetic Mice. Cell studies show it can protect blood vessel linings from high glucose damage [Gly14]-Humanin ameliorates high glucose-induced endothelial senescence via SIRT6.

Lung and Inflammatory Protection

In mice with acute lung injury, Humanin reduced inflammation and improved lung function, partly through AMPK activation Humanin-G Ameliorates Hemorrhage-Induced Acute Lung Injury in Mice Through AMPKα1-Dependent and -Independent Mechanisms. It also lowered inflammatory signals in retinal cells related to age-related macular degeneration Characterization of the Effects of a Humanin Fragment Peptide (HNF14) in Age-Related Macular Degeneration.

Overall, the research shows broad protective effects, but most findings are from animal or cell models. Human trials are still needed.

Most Humanin research uses injectable forms, often analogs like HNG (S14G-Humanin) that are more potent than the native peptide A humanin derivative, S14G‐HN, prevents amyloid‐β‐induced memory impairment in mice. In animal studies, dosing varies widely by route and condition:

• Stroke models: A single dose of 0.1 µg HNG injected directly into the brain or 1 µg into the abdomen provided significant reduction in brain damage Humanin Is a Novel Neuroprotective Agent Against Stroke.
• Diabetes models: Repeated daily injections of 4 mg/kg into the abdomen for 15 days restored hormone balance in mice Humanin Restores Metabolic Hormone Homeostasis of Leptin, Ghrelin, Irisin and Asprosin in Streptozotocin-Induced Diabetic Mice.
• Lung injury models: A single dose of PEGylated Humanin-G after hemorrhagic shock reduced lung inflammation Humanin-G Ameliorates Hemorrhage-Induced Acute Lung Injury in Mice Through AMPKα1-Dependent and -Independent Mechanisms.

For research using subcutaneous injection, community protocols often adopt daily doses between 0.5 mg and 2 mg, with cycles lasting 4 to 8 weeks [community protocol]. The lack of human pharmacokinetic data means these doses are empirically derived, not optimized through clinical trials.

Intranasal administration is sometimes chosen for brain-focused studies, based on animal work showing direct nose-to-brain delivery Intranasal delivery of mitochondrial protein humanin rescues cell death and promotes mitochondrial function in Parkinson's disease.

Humanin is typically supplied as a lyophilized powder that must be mixed with a diluent before use. Bacteriostatic water is the standard choice for multi-dose vials, as it helps prevent bacterial growth [community protocol]. After adding the diluent, gently swirl the vial to dissolve the powder; avoid vigorous shaking to prevent foaming and peptide damage [community protocol].

Once reconstituted, store the solution in the refrigerator at 2-8°C. Most users aim to use the product within 30 days to maintain potency, though some freeze aliquots for longer storage at -20°C [community protocol]. For intranasal use, keep a separate sterile aliquot to reduce contamination risk, since intranasal delivery has been used in Parkinson's disease research Intranasal delivery of mitochondrial protein humanin rescues cell death and promotes mitochondrial function in Parkinson's disease.

Always discard any solution that becomes cloudy, discolored, or contains particles.

Humanin influences many signaling pathways, so it could interact with other drugs and supplements, though formal interaction studies are lacking [mechanistic]. Here are the key theoretical considerations:

• Diabetes medications: Humanin may add to the glucose-lowering effects of insulin, metformin, or GLP-1 agonists, so blood sugar should be monitored more closely Humanin Restores Metabolic Hormone Homeostasis of Leptin, Ghrelin, Irisin and Asprosin in Streptozotocin-Induced Diabetic Mice+1.
• Blood pressure drugs: Since Humanin can affect vascular function, it might enhance the effects of antihypertensives, possibly leading to dizziness or low blood pressure Humanin-G Ameliorates Hemorrhage-Induced Acute Lung Injury in Mice Through AMPKα1-Dependent and -Independent Mechanisms+1.
• Chemotherapy: Because Humanin protects cells from death, it could theoretically interfere with cancer treatments that rely on killing tumor cells Humanin: A Multifactorial Anti-death Agent. Avoid use during active cancer therapy unless supervised.
• Peptide combinations: Stacking Humanin with other mitochondrial peptides like MOTS-c or SS-31 is common in research, but effects may overlap, making it hard to attribute benefits [community protocol].

For supplements, Humanin may work synergistically with antioxidants like NAC and berberine, but additive effects on blood sugar and blood pressure warrant caution Effects of N-Acetylcysteine on Humanin and Endostatin in Rats Exposed to Formaldehyde+1.

Humanin is not typically used continuously in research protocols. Instead, cyclic patterns are favored, partly because animal studies show that short courses can produce lasting benefits Enduring Effects of Humanin on Mitochondrial Systems in TBI Pathology+1. For example, a single early dose after traumatic brain injury improved cognitive outcomes weeks later Enduring Effects of Humanin on Mitochondrial Systems in TBI Pathology.

Common cycling approaches include:

• 4 to 6 weeks on, 2 to 4 weeks off for general mitochondrial support [community protocol].
• 6 to 8 weeks on, 4 weeks off for neuroprotection [community protocol].
• Shorter 2 to 4 week blocks for metabolic reset, often paired with diet or exercise interventions [community protocol].

The rationale for cycling is to allow the body's stress-response systems to reset and to reduce the unknown risks of prolonged exposure. There is no evidence that Humanin causes dependence or withdrawal.

Humanin is often combined with other peptides to target multiple aspects of health. Research and community practice suggest several synergistic stacks:

• With BPC-157 or TB-500: These healing peptides may complement Humanin's tissue-protective effects, creating a broad recovery stack Humanin: A Multifactorial Anti-death Agent[community protocol].
• With GLP-1 agonists (e.g., semaglutide): Combined for metabolic health, as Humanin's insulin-sensitizing and anti-inflammatory actions may enhance weight loss and glucose control Humanin Restores Metabolic Hormone Homeostasis of Leptin, Ghrelin, Irisin and Asprosin in Streptozotocin-Induced Diabetic Mice+1.
• With mitochondrial peptides like MOTS-c or SS-31: These stack to amplify mitochondrial support and energy metabolism, though response attribution becomes difficult [community protocol].
• For brain health: Humanin is sometimes stacked with Semax or Cerebrolysin, but evidence for these combinations is purely anecdotal [community protocol].

Because Humanin affects cell survival pathways, avoid stacking with any therapy that relies on inducing cell death, such as certain cancer treatments.

Humanin is not FDA-approved for any medical condition Humanin: a mitochondrial signaling peptide as a biomarker for impaired fasting glucose-related oxidative stress+1. It remains an investigational compound, with most evidence coming from animal and cell studies. No country has approved it as a drug, based on the available literature.

In the United States, Humanin is not scheduled as a controlled substance, but it falls under research-peptide regulations. Selling it for human use would likely violate FDA rules on unapproved drugs. For athletes, Humanin is not explicitly listed on the WADA Prohibited List, but it has not been cleared for use in competition. Because it is an exogenous peptide with biological activity, its use could be considered a violation under catch-all rules.

The legal landscape is evolving. Researchers and practitioners should verify local regulations before obtaining or using Humanin.

Humanin has not undergone systematic safety testing in humans, so its side effect profile is based on animal studies and theoretical considerations The emerging role of the mitochondrial-derived peptide humanin in stress resistance+1. In animal models, it is generally well-tolerated, with no clear signs of organ toxicity at studied doses.

Potential side effects reported in community use include mild injection-site reactions, headache, fatigue, or temporary changes in appetite [community protocol]. More serious concerns are theoretical: because Humanin blocks cell death, there is a concern it could, in theory, protect cancerous cells or interfere with cancer therapy Humanin: A Multifactorial Anti-death Agent+1. This has not been observed but remains a caution.

Other theoretical risks include blood pressure changes, interactions with diabetes medications, and effects on retinal blood vessels (based on its anti-VEGF activity in the eye) Humanin-G Ameliorates Hemorrhage-Induced Acute Lung Injury in Mice Through AMPKα1-Dependent and -Independent Mechanisms+1.

Currently, Humanin should be considered experimental, with unknown long-term safety. Anyone considering its use should weigh these uncertainties and monitor relevant health markers.